A prospective, multicenter, open study of fluconazole prophylaxis was performed in AIDS patients to evaluate the efficacy and toxicity of the drug in preventing relapses of esophageal candidiasis. To this aim, 99 AIDS patients who presented a first episode of clinically and microbiologically confirmed esophageal candidiasis were enrolled in eleven clinical centers scattered throughout the Italian territory. After resolution of this initial esophagitis, all subjects were given fluconazole, 100 mg/die, and followed up for a 6 month period. Only 7 out of the 99 patients enrolled had a relapse ofCandida esophagitis, during a mean follow-up period of 138.5 days. All relapsing patients had CD4+ cell number <100/µl at baseline. Mild side effects were reported in only eight patients. However, 14 of the 27 subjects from whom serial serum samples were available became (12) or remained (2) antigenemic during fluconazole prophylaxis, independently from relapse, suggesting the persistence of tissue-invasive, proliferatingCandida cells. Overall, the data of this study suggest a beneficial effect of prophylactic maintenance therapy with fluconazole againstCandida esophagitis, particularly in the population with >100 CD4+/µl. However, the data onCandida antigenemia in these patients invite the consideration of a relative inefficiency of the drug to eradicate the microrganism from the esophageal tissue.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Calhoum DL, Galgiani JN. The imidazoles: Miconazole, ketoconazole. Antimicrob Agents Ann 1986; 1: 218–228.
De Wit S, Weerts D, Goossens H, Clumek N. Comparison of fluconazole and ketoconazole for oropharyngeal candidiasis in AIDS. Lancet 1989(i): 746–748.
De Wit S, Urbain D, Rahir F, Weerts D, Clumek N. Efficacy of oral fluconazole in the treatment of AIDS — associated oesopharyngeal candidiasis. Eur J Clin Microbiol Infect 1991; 10: 503–505.
Shadomy S, Pfaller MA. Laboratory studies with antifungal agents: Susceptibility tests and quantitation in body fluids. In Balows A, Hausler J, Herrmann KL, Isenberg MD, Shadomy JH, eds, Manual of clinical microbiology, 5th ed. Washington, DC: American Society for Microbiology, Chap. 117, p. 1173.
Van Cutsem J, Van Gerven F, Janssen PAJ. Activity of orally, topically and parenterally administered itraconazole in the treatment of superficial and deep mycoses: Animal models. Rev Infect Dis 1987; 9 (suppl 1): 515–532.
Brammer KW, Farrow PR, Faulkner JK. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis 1990; 12 (suppl) 3: 318–326.
Agatensi L, Franchi F, Mondello F, Bevilacqua R, Ceddia T, De Bernardis F, Cassone A. Vaginopathic and proteolyticCandida species attending a gynecologic clinic. J Clin Pathol 1991; 44: 826–830.
Meyer SA, Ahearn DG, Yarrow D. GENUS 4Candida Berkhout. In: Kreger NJW, ed. The yeasts: A taxonomic study. Amsterdam: Elsevier, 1984: 746–747.
Venditti M, De Bernardis F, Micozzi A, Pontieri E, Chirletti P, Cassone A, Martino P. Fluconazole treatment of catheter-related right-sided endocarditis caused byCandida albicans and associated with endophthalmitis and folliculitis. Clin Infect Dis 1992; 14: 422–426.
De Bernardis F, Girmenia C, Boccanera M, Adriani D, Martino P, Cassone A. The use of a monoclonal antibody in a dot-immunobinding assay for detection of a circulating mannoprotein ofCandida spp. in neutropenic patients with invasive candidiasis. J Clin Microbiol 1993; 31: 3142–3146.
Torosantucci A, Boccanera M, Casalinuovo I, Pellegrini G, Cassone A. Differences in the antigenic expression of immunomodulatory mannoprotein constituents on yeast and mycelial forms ofCandida albicans. J Gen Microbiol 1990; 136: 1421–1428.
British Society for Antimicrobial Chemotherapy Working Party. Antifungal chemotherapy in patients with Acquired Immunodeficiency Syndrome. Lancet 1992; 340: 648–651.
Chave JP, Francioli P, Hirschel B, Glauser MP. Single dose therapy for esophageal candidiasis with fluconazole. AIDS 1990; 4: 1033–1042.
Hay RJ. Overview of studies of fluconazole in oropharyngeal candidiasis. Rev Infect Dis 1990; 12 (suppl) 3: 334–337.
Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp Je, Saral R. Increase inCandida krusei infection among patients with fluconazole. N Engl J Med 1991; 1325: 1274–1277.
Dupont B, Drouhet E. Fluconazole in the management of oropharyngeal candidiasis in a predominantly HIV antibody-positive group of patients. J Med Vet Mycol 1988; 26: 67–71.
Samonis G, Rolston K, Karl C. Prophylaxis of oropharyngeal candidiasis with fluconazole. Rev Infect Dis 1990; 12 (suppl) 3: 370–373.
Hay RJ. Fluconazole. J Infect 1990; 21: 1–6.
Grunewald TH, Sandfort J, Bergman F, Ruj B. Prevention of symptomatic candidiasis with biweekly fluconazole in HIV-infected patients. 32nd International Conference on Antimicrobial Agents and Chemotherapy, Anhaeim, CA, USA, 1992: Abstract 1116.
Lazar JD, Wilner KD. Drug interaction with fluconazole. Rev Infect Dis 1990; 12 (suppl) 3: 328–333.
De Repentigny L, Reiss E. Current trends in immunodiagnosis of candidiasis and aspergillosis. Rev Infect Dis 1984; 6: 301–312.
Dupont B, Improvisi L, Elaszewics M, Pialoux G, Gemo: Resistance ofCandida albicans to fluconazole in AIDS patients. 32nd International Conference on Antimicrobial Agents and Chemotherapy, Anhaeim, CA, USA, 1992: Abstract 1203.
Warnock DW, Burke J, Cope NJ, Johnson EM, Von Fraunhofer NA, Williams EW. Fluconazole resistance inCandida glabrata. Lancet 1988 (ii): 1310.
About this article
Cite this article
Agresti, M.G., de Bernardis, F., Mondello, F. et al. Clinical and mycological evaluation of fluconazole in the secondary prophylaxis of esophageal candidiasis in AIDS patients. Eur J Epidemiol 10, 17–22 (1994). https://doi.org/10.1007/BF01717446
- Candidal esophagitis
- Fluconazole prophylaxis